パーキンソン病治療薬市場：薬剤クラス別、投与経路別、剤形別、対象領域別、流通チャネル別-2025年～2030年の世界予測

パーキンソン病治療薬市場は、2024年には58億1,000万米ドルとなり、2025年には61億4,000万米ドル、CAGR 5.93%で成長し、2030年には82億1,000万米ドルに達すると予測されています。

パーキンソン病は、最も困難な神経変性疾患の一つとして位置づけられ、治療アプローチの継続的な革新が求められています。近年、調査や臨床試験により、この複雑な疾患の運動症状だけでなく非運動面にも対応する、漸進的かつ画期的な進歩が見られるようになりました。治療法の進化は、精密医療と個別化された治療計画がますます患者の治療に不可欠となる新時代の到来を告げています。現在の治療パラダイムは、疾患経路のより深い理解、診断技術の向上、副作用の軽減と患者の転帰の改善を目指した新しいドラッグデリバリー法によって強化されつつあります。

このイントロダクションは、パーキンソン病治療薬に影響を及ぼす多面的な力学に関する、しっかりとした議論のための舞台を整えるものです。将来の治療方針を決定するためには、臨床医、研究者、産業界の専門家の継続的な協力が不可欠であることに留意することが重要です。包括的な視点を育むことで、利害関係者は規制要件、償還モデル、患者の期待の変化をより的確に予測することができます。科学と技術の融合は治療アルゴリズムを再定義し、患者にも介護者にも希望を与えています。本サマリーでは、この後のセクションに進むにあたり、この進化する分野における戦略的意思決定に役立つ、変革的シフト、セグメンテーションに関する洞察、世界の地域ダイナミックス、影響力のある市場プレイヤー、実行可能な提言について概説することで、必要な背景を提供します。

パーキンソン病治療薬市場の変革

ここ数年、パーキンソン病治療において変革的な変化が起きており、旧来のパラダイムが再構築され、革新的な治療法が導入されています。こうした転換は、治療介入の考え方や方法を再定義する画期的な研究によってもたらされました。神経薬理学の進歩により、現在ではドパミン作動性システムのより標的を絞った調節が可能となり、また新たな技術によりドラッグデリバリーの精度が向上しています。この勢いを後押ししているのは、臨床試験デザインの改善であり、長期的な有効性と安全性にますます焦点が当てられるようになっています。

同時に、疾患の異質性への理解が深まったことで、医師は画一的なアプローチを再考せざるを得なくなりました。業界は現在、患者固有の遺伝子や症状プロファイルを考慮した個別化治療レジメンを重視しています。この個別化は臨床転帰を最適化するだけでなく、従来の治療法に伴う副作用の軽減にも役立ちます。さらに、デジタルヘルスソリューションと遠隔患者モニタリングは、疾患の進行管理に不可欠なものとなりつつあり、臨床医がほぼリアルタイムで治療戦略を調整することを可能にしています。学術機関とバイオテクノロジー企業の共同研究は、実験室での発見とベッドサイドでの応用のギャップを急速に埋めつつあり、パーキンソン病治療薬における前例のない成長と革新の時代の舞台を整えつつあります。

市場セグメンテーションによる主な洞察

パーキンソン病治療薬分野の市場セグメンテーションは、特定の患者のニーズを満たすために治療戦略が多様化されている無数の方法に関する重要な洞察を提供します。薬剤クラス別のセグメンテーションでは、抗コリン薬、カルビドパ・レボドパ、COMT阻害薬、ドパミンアゴニスト、MAO-B阻害薬などの治療オプションを研究しています。この分類により、異なるクラスがどのように異なる治療効果を発揮するのか、また特定の患者プロファイルに対してどのように最適化できるのかについて、微妙な理解が容易になります。

さらに、投与経路による区分は、望ましい薬物動態プロファイルを達成する上で、腸管注入、経口手法、皮下注射、局所適用が果たす重要な役割を浮き彫りにします。さらに薬剤の形態別に分けると、注射剤、錠剤、カプセル剤、経皮パッチ剤などの製剤が患者のコンプライアンスと有効性に与える影響が明らかになります。さらに、非定型パーキンソン病、薬剤誘発性パーキンソン病、遺伝性パーキンソン病、特発性パーキンソン病、血管性パーキンソン病に関連する治療について、対象領域のセグメンテーションを行うことで、疾患の多様なプレゼンテーションがいかに異なる治療経路を必要とするかを明らかにしています。最後に、病院薬局、オンライン薬局、小売薬局を評価した流通チャネルのセグメンテーションは、進化する消費者行動と、より幅広いアクセスを保証するヘルスケア提供モデルの適応を示しています。

この詳細なセグメンテーションは、精度を高め、より効果的に治療法を調整し、最終的には患者ケアの全体的な軌道を改善するという業界の推進力を強調しています。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で高齢者人口が増加し、パーキンソン病の発症率も上昇
    • バイオマーカーの特定と遺伝子調査による個別化医療アプローチの出現
    • 強化されたヘルスケアインフラと専門神経学センターへのアクセスの改善
  • 抑制要因
    • 副作用のリスクが高く、患者の遵守と全体的な受容を低下させる
  • 機会
    • AIアルゴリズムとビッグデータ分析を統合し、個別治療の予測モデルを最適化する
    • 早期診断検査と高度な画像技術への投資の増加により、タイムリーな検出が容易になる
  • 課題
    • 複雑な規制枠組みと、さまざまな地域にわたる厳格なコンプライアンス基準の遵守
• 市場セグメンテーション分析
  • 薬物クラス：脳に入るレボドパの量を増やすためにLovopoda薬物クラスが好まれる傾向が高まっている
  • 対象分野：薬剤誘発性パーキンソン病における薬剤によって引き起こされる神経学的影響の解明
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 パーキンソン病治療薬市場薬剤クラス別

• 抗コリン薬
• カルビドパ-レボドパ
• COMT阻害剤
• ドーパミン作動薬
• MAO-B阻害剤

第7章 パーキンソン病治療薬市場：投与経路別

• 腸内注入
• オーラル
• 皮下
• トピック

第8章 パーキンソン病治療薬市場薬剤形態別

• 注射
• 錠剤とカプセル
• 経皮パッチ

第9章 パーキンソン病治療薬市場対象エリア別

• 非定型パーキンソン病
• 薬剤誘発性パーキンソン病
• 遺伝性パーキンソン病
• 特発性パーキンソン病
• 血管性パーキンソン病

第10章 パーキンソン病治療薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第11章 南北アメリカのパーキンソン病治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域のパーキンソン病治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカのパーキンソン病治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Apotex Inc.
• Aurobindo Pharma Limited
• Biogen Inc
• Bristol-Myers Squibb Company
• Cadila Healthcare Limited
• Cipla Limited
• Eisai Co., Ltd.
• Eli Lilly and Company
• GlaxoSmithKline plc
• Glenmark Pharmaceuticals Ltd.
• H. Lundbeck A/S
• Hikma Pharmaceuticals PLC
• Lupin Limited
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Sumitomo Dainippon Pharma Co., Ltd.
• Teva Pharmaceutical Industries Limited
• TORRENT PHARMACEUTICALS LTD
• UCB S.A.

LIST OF FIGURES

• FIGURE 1. PARKINSON'S DISEASE THERAPEUTICS MARKET MULTI-CURRENCY
• FIGURE 2. PARKINSON'S DISEASE THERAPEUTICS MARKET MULTI-LANGUAGE
• FIGURE 3. PARKINSON'S DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 4. PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 19. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 21. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. PARKINSON'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 27. PARKINSON'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. PARKINSON'S DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PARKINSON'S DISEASE THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY CARBIDOPA-LEVODOPA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COMT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DOPAMINE AGONISTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY MAO-B INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INTESTINAL INFUSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TABLETS & CAPSULES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ATYPICAL PARKINSONIAN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG-INDUCED PARKINSONISM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY GENETIC PARKINSON'S, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY IDIOPATHIC PARKINSON'S, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY VASCULAR PARKINSONISM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 48. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 49. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 50. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 51. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 52. CANADA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 57. MEXICO PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 63. UNITED STATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 69. ASIA-PACIFIC PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 72. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 73. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 74. AUSTRALIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 75. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 76. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 77. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 78. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 79. CHINA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 81. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 82. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 83. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 84. INDIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 87. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 88. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 89. INDONESIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 92. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 93. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 94. JAPAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 97. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 98. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 99. MALAYSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 102. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 103. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 104. PHILIPPINES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 107. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 108. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 109. SINGAPORE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 112. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 113. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 114. SOUTH KOREA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 117. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 118. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 119. TAIWAN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 122. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 123. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 124. THAILAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 127. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 128. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 129. VIETNAM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 134. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 135. EUROPE, MIDDLE EAST & AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 138. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 139. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 140. DENMARK PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 143. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 144. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 145. EGYPT PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 148. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 149. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 150. FINLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 153. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 154. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 155. FRANCE PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 158. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 159. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 160. GERMANY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 163. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 164. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 165. ISRAEL PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 166. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 167. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 168. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 169. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 170. ITALY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 173. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 174. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 175. NETHERLANDS PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 178. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 179. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 180. NIGERIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 183. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 184. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 185. NORWAY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 186. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 187. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 188. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 189. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 190. POLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 191. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 192. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 193. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 194. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 195. QATAR PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 198. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 199. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 200. RUSSIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 203. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 204. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 205. SAUDI ARABIA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 210. SOUTH AFRICA PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 213. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 214. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 215. SPAIN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 218. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 219. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 220. SWEDEN PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 223. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 224. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 225. SWITZERLAND PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 228. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 229. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 230. TURKEY PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 233. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 234. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 235. UNITED ARAB EMIRATES PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 238. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DRUG FORM, 2018-2030 (USD MILLION)
• TABLE 239. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY TARGETED AREA, 2018-2030 (USD MILLION)
• TABLE 240. UNITED KINGDOM PARKINSON'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 241. PARKINSON'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 242. PARKINSON'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

The Parkinson's Disease Therapeutics Market was valued at USD 5.81 billion in 2024 and is projected to grow to USD 6.14 billion in 2025, with a CAGR of 5.93%, reaching USD 8.21 billion by 2030.

Parkinson's disease continues to stand as one of the most challenging neurodegenerative conditions, demanding continuous innovation in therapeutic approaches. In recent years, research and clinical trials have led to both incremental and revolutionary advancements that not only address the motor symptoms but also the non-motor aspects of this complex condition. The evolving landscape of therapeutics has ushered a new era where precision medicine and personalized treatment plans are increasingly becoming integral to patient care. Current treatment paradigms are being reinforced by a deeper understanding of disease pathways, improved diagnostic techniques, and novel drug delivery methods that aim to reduce side effects and enhance patient outcomes.

This introduction sets the stage for a robust discussion on the multifaceted dynamics influencing Parkinson's disease therapeutics. It is important to note that continuous collaboration between clinicians, researchers, and industry experts is critical in defining the future course of therapy. By fostering a comprehensive perspective, stakeholders can better anticipate shifts in regulatory requirements, reimbursement models, and patient expectations. The convergence of science and technology is redefining treatment algorithms, offering hope to patients and caregivers alike. As we delve into the subsequent sections, this summary provides the necessary context by outlining the transformative shifts, segmentation insights, global regional dynamics, influential market players, and actionable recommendations that will inform strategic decisions in this evolving field.

Transformative Shifts in the Therapeutic Landscape

Recent years have brought transformative shifts in the therapeutic landscape of Parkinson's disease, reshaping old paradigms and introducing innovative treatment modalities. These shifts are driven by groundbreaking research that has redefined how therapeutic interventions are conceived and administered. Advances in neuropharmacology now enable more targeted modulation of the dopaminergic system, while emerging technologies offer improved precision in drug delivery. Driving this momentum are improved clinical trial designs, which have increasingly focused on long-term efficacy and safety, ensuring that novel therapies are both sustainable and accessible to a broader patient base.

Concurrently, an enhanced understanding of disease heterogeneity has forced practitioners to reconsider one-size-fits-all approaches. The industry is now emphasizing individualized treatment regimens that account for a patient's unique genetic and symptomatic profile. This personalization not only optimizes clinical outcomes but also helps in mitigating adverse effects associated with traditional therapies. Additionally, digital health solutions and remote patient monitoring are becoming integral in managing disease progression, enabling clinicians to adjust therapeutic strategies in near real time. Collaborative research across academic institutions and biotech companies is rapidly bridging the gap between laboratory discoveries and bedside applications, setting the stage for a period of unprecedented growth and innovation in Parkinson's therapeutics.

Key Insights from Market Segmentation

Market segmentation in the field of Parkinson's disease therapeutics provides critical insight into the myriad ways in which treatment strategies are being diversified to meet specific patient needs. The segmentation based on drug class involves a spectrum of treatment options studying anticholinergics, Carbidopa-Levodopa, COMT inhibitors, dopamine agonists, and MAO-B inhibitors. This classification facilitates a nuanced understanding of how different classes exert distinct therapeutic benefits and how they can be optimized for specific patient profiles.

Moreover, segmentation by route of administration highlights the significant roles played by intestinal infusion, oral methodologies, subcutaneous injections, and topical applications in achieving desired pharmacokinetic profiles. A further split based on drug form elucidates the impact of formulations such as injections, tablets and capsules, as well as transdermal patches on patient compliance and efficacy. Additionally, a targeted area segmentation sheds light on treatments associated with atypical Parkinsonian conditions, drug-induced Parkinsonism, genetic Parkinson's, idiopathic Parkinson's, and vascular Parkinsonism, emphasizing how variant presentations of the disease necessitate different therapeutic pathways. Lastly, the distribution channel segmentation, which evaluates hospital pharmacy, online pharmacy, and retail pharmacy outlets, is indicative of evolving consumer behaviors and adapting healthcare delivery models that ensure wider accessibility.

This detailed segmentation underscores the industry's drive to harness precision, tailor therapies more effectively, and ultimately improve the overall trajectory of patient care.

Based on Drug Class, market is studied across Anticholinergics, Carbidopa-Levodopa, COMT inhibitors, Dopamine Agonists, and MAO-B Inhibitors.

Based on Route Of Administration, market is studied across Intestinal Infusion, Oral, Subcutaneous, and Topical.

Based on Drug Form, market is studied across Injections, Tablets & Capsules, and Transdermal Patches.

Based on Targeted Area, market is studied across Atypical Parkinsonian, Drug-Induced Parkinsonism, Genetic Parkinson's, Idiopathic Parkinson's, and Vascular Parkinsonism.

Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.

Regional Dynamics Influencing Therapeutic Adoption

An analysis of the regional landscape uncovers significant variations in how Parkinson's disease therapeutics are adopted and integrated across different markets. The Americas have demonstrated a robust infrastructure backed by substantial investments in advanced research and state-of-the-art clinical practices. Meanwhile, regions encompassing Europe, the Middle East, and Africa are marked by proactive regulatory frameworks and a surge in collaborative alliances between governments and pharmaceutical innovators, thereby fostering an environment conducive to breakthrough therapies. In the Asia-Pacific region, rapid economic growth combined with increasing healthcare expenditure and a rising incidence of Parkinson's disease has driven remarkable advancements in treatment modalities and delivery systems.

These regional insights illustrate that while challenges remain in standardizing care across diverse healthcare settings, the evolving global landscape offers unique opportunities to harmonize research efforts and address patient needs more effectively. The interplay between regulatory reforms, funding allocations, and cultural nuances in each region further shapes the adoption curve and paves the way for strategic market entry and expansion.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Influential Companies Shaping the Market

Key market players are at the forefront of revolutionizing Parkinson's disease therapeutics, driving innovation and operational excellence in the sector. Industry leaders such as Apotex Inc. and Aurobindo Pharma Limited have consistently pushed the boundaries in generic formulation development, while companies like Biogen Inc. and Bristol-Myers Squibb Company leverage extensive research pipelines to deliver precision therapies. Cadila Healthcare Limited and Cipla Limited continue to strengthen their market presence through affordable yet effective treatment solutions.

Global pharmaceutical titans including Eisai Co., Ltd., Eli Lilly and Company, and GlaxoSmithKline plc have contributed significantly to the development of advanced drug formulations that emphasize both efficacy and patient convenience. In parallel, organizations such as Glenmark Pharmaceuticals Ltd., H. Lundbeck A/S, and Hikma Pharmaceuticals PLC are pivotal in initiating clinical studies that explore novel therapeutic mechanisms. Other influential companies like Lupin Limited, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, and Novartis AG have been instrumental in adapting to rapid market shifts through strategic investments in research and development. Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sumitomo Dainippon Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, TORRENT PHARMACEUTICALS LTD, and UCB S.A. are equally contributing to this dynamic scenario by pushing forward innovative treatments that cater to diverse patient demographics.

Together, these companies form an ecosystem that not only drives clinical advancements but also fosters a competitive environment where continual improvement becomes the norm, ensuring that patients benefit from the most updated and effective treatment strategies available.

The report delves into recent significant developments in the Parkinson's Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Apotex Inc., Aurobindo Pharma Limited, Biogen Inc, Bristol-Myers Squibb Company, Cadila Healthcare Limited, Cipla Limited, Eisai Co., Ltd., Eli Lilly and Company, GlaxoSmithKline plc, Glenmark Pharmaceuticals Ltd., H. Lundbeck A/S, Hikma Pharmaceuticals PLC, Lupin Limited, Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sumitomo Dainippon Pharma Co., Ltd., Teva Pharmaceutical Industries Limited, TORRENT PHARMACEUTICALS LTD, and UCB S.A.. Actionable Recommendations for Industry Leaders

For stakeholders within Parkinson's disease therapeutics, strategic planning and investment are crucial in navigating this evolving market. Industry leaders are advised to concentrate on the development of therapies that not only address motor symptoms but also work to mitigate non-motor manifestations, thus offering holistic patient care. Identifying and capitalizing on emerging trends in precision medicine and targeted drug delivery will serve as key differentiators in an increasingly competitive arena. It is essential to invest in advanced research collaborations and clinical trials that explore multi-faceted treatment options, thereby reducing time-to-market for innovative drug solutions.

Fostering partnerships with academic institutions, biotech firms, and healthcare providers can greatly enhance the ability to personalize treatments for varied patient profiles. Leaders are encouraged to bolster digital platforms that support telemedicine and remote patient monitoring, enabling more efficient and timely adjustments in therapy regimens. Additionally, an emphasis on regulatory compliance, market authorization processes, and strategic communication with policymakers is critical to ensure seamless market entry and sustained growth. By streamlining operations and leveraging cutting-edge technological solutions, decision-makers can enhance patient engagement, optimize supply chain logistics, and ultimately secure a competitive advantage in a rapidly transforming market.

In summary, a forward-thinking approach that embraces innovation, collaboration, and adaptability will be key to transforming challenges into opportunities, ensuring long-term success in the therapeutic landscape.

Conclusion: Navigating the Evolving Therapeutic Sphere

The continuous evolution in Parkinson's disease therapeutics is a testament to the remarkable strides achieved by industry experts, researchers, and clinicians alike. As the treatment landscape expands, a multi-pronged approach that involves advanced drug formulations, innovative delivery systems, and personalized care models becomes indispensable. Reflection on the recent transformative shifts, detailed segmentation insights, profound regional dynamics, and influential market players reveals a sector in vigorous transformation.

The synthesis of robust clinical data, technological innovations, and strategic market insights underscores the potential for enhanced patient outcomes and improved quality of life. While challenges remain, the collaborative efforts across scientific, regulatory, and commercial domains represent a driving force that is reshaping the future of neurodegenerative disease management. With a commitment to continuous improvement and adaptive strategies, the industry is well-positioned to tackle the complexities inherent in Parkinson's disease, paving the way for more effective and patient-centric therapies.

Ultimately, this journey is not only about overcoming the limitations of current treatment paradigms but also about laying a solid foundation for tomorrow's breakthroughs. The integration of diverse insights and actionable strategies will continue to steer the industry toward a future where innovation serves as the cornerstone for better health outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing elderly population with rising incidence rates of Parkinson's disease globally
    • 5.1.1.2. Emergence of personalized medicine approaches through biomarker identification and genetic research
    • 5.1.1.3. Enhanced healthcare infrastructure and improved access to specialized neurology centers
  • 5.1.2. Restraints
    • 5.1.2.1. High risk of adverse side effects reducing patient adherence and overall acceptance
  • 5.1.3. Opportunities
    • 5.1.3.1. Integration of AI algorithms and big data analytics to optimize predictive models for individualized treatment
    • 5.1.3.2. Rising investments in early diagnostic testing and advanced imaging techniques to facilitate timely detection
  • 5.1.4. Challenges
    • 5.1.4.1. Complex regulatory frameworks and meeting rigorous compliance standards across different region
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Class: Growing preference for Lovopoda drug class to enhances the amount of levodopa entering the brain
  • 5.2.2. Targeted Area: Unraveling the neurological effects triggered by medication in drug-induced parkinsonism
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Parkinson's Disease Therapeutics Market, by Drug Class

• 6.1. Introduction
• 6.2. Anticholinergics
• 6.3. Carbidopa-Levodopa
• 6.4. COMT inhibitors
• 6.5. Dopamine Agonists
• 6.6. MAO-B Inhibitors

7. Parkinson's Disease Therapeutics Market, by Route Of Administration

• 7.1. Introduction
• 7.2. Intestinal Infusion
• 7.3. Oral
• 7.4. Subcutaneous
• 7.5. Topical

8. Parkinson's Disease Therapeutics Market, by Drug Form

• 8.1. Introduction
• 8.2. Injections
• 8.3. Tablets & Capsules
• 8.4. Transdermal Patches

9. Parkinson's Disease Therapeutics Market, by Targeted Area

• 9.1. Introduction
• 9.2. Atypical Parkinsonian
• 9.3. Drug-Induced Parkinsonism
• 9.4. Genetic Parkinson's
• 9.5. Idiopathic Parkinson's
• 9.6. Vascular Parkinsonism

10. Parkinson's Disease Therapeutics Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacy
• 10.3. Online Pharmacy
• 10.4. Retail Pharmacy

11. Americas Parkinson's Disease Therapeutics Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Parkinson's Disease Therapeutics Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Parkinson's Disease Therapeutics Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Mitsubishi Tanabe Pharma America unveils three-tear data for ND0612 in parkinson's disease
  • 14.3.2. Vesalius and GSK forge alliance to Parkinson's treatment
  • 14.3.3. New immunoassay platform enhances parkinson's disease research
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Apotex Inc.
• 2. Aurobindo Pharma Limited
• 3. Biogen Inc
• 4. Bristol-Myers Squibb Company
• 5. Cadila Healthcare Limited
• 6. Cipla Limited
• 7. Eisai Co., Ltd.
• 8. Eli Lilly and Company
• 9. GlaxoSmithKline plc
• 10. Glenmark Pharmaceuticals Ltd.
• 11. H. Lundbeck A/S
• 12. Hikma Pharmaceuticals PLC
• 13. Lupin Limited
• 14. Merck & Co., Inc.
• 15. Mitsubishi Tanabe Pharma Corporation
• 16. Novartis AG
• 17. Otsuka Pharmaceutical Co., Ltd.
• 18. Pfizer Inc.
• 19. Sumitomo Dainippon Pharma Co., Ltd.
• 20. Teva Pharmaceutical Industries Limited
• 21. TORRENT PHARMACEUTICALS LTD
• 22. UCB S.A.